Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.66 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.66 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.66 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.66 |
| ▸ | DPP4 | P27487 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.66 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.66 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.66 |
| ▸ | GAPDH | P04406 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | STAT6 | P42226 | 1/20 | 0.66 |
| ▸ | PI4KA | P42356 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.66 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.66 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.66 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.66 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24872346 | 1.00 | ADORA1 (0.66) | ADORA1ADORA2AADORA2BADORA3DPP4 | |
| SCHEMBL4456275 | 1.00 | ADORA1 (0.66) | ADORA1ADORA2AADORA2BADORA3DPP4 | |
| SCHEMBL24968581 | 1.00 | ADORA1 (0.66) | ADORA1ADORA2AADORA2BADORA3DPP4 | |
| SCHEMBL30605195 | 1.00 | ADORA1 (0.66) | ADORA1ADORA2AADORA2BADORA3DPP4 | |
| SCHEMBL4456272 | 1.00 | ADORA1 (0.66) | ADORA1ADORA2AADORA2BADORA3DPP4 | |
| SCHEMBL25284573 | 1.00 | ADORA1 (0.66) | ADORA1ADORA2AADORA2BADORA3DPP4 | |
| SCHEMBL6261501 | 0.99 | ADORA2A (0.67) | ADORA1ADORA2AADORA2BADORA3DPP4 | |
| SCHEMBL8007481 | 0.99 | ADORA2A (0.67) | ADORA1ADORA2AADORA2BADORA3DPP4 | |
| SCHEMBL8007474 | 0.99 | ADORA2A (0.67) | ADORA1ADORA2AADORA2BADORA3DPP4 | |
| SCHEMBL29705813 | 0.99 | ADORA2A (0.67) | ADORA1ADORA2AADORA2BADORA3DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139257-A1 | PLIN1 RNAi INTERFERENCE AGENTS | ELI LILLY AND CO (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4720284-A2 | NOVEL SCN10A RNAI AGENTS AND USES THEREOF | Eli Lilly and Company (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20250188472-A1 | SARM1 RNA INTERFERENCE AGENTS | ELI LILLY AND COMPANY | 2025-06-12 | — | — | US | disclosed |
| US-20250179491-A1 | ATXN2 RNA INTERFERENCE AGENTS | ELI LILLY AND COMPANY | 2025-06-05 | — | — | US | disclosed |
| EP-4493692-A1 | SARM1 RNA INTERFERENCE AGENTS | Eli Lilly and Company (US) | 2025-01-22 | — | — | EP | disclosed |
| WO-2024249240-A2 | NOVEL SCN10A RNAI AGENTS AND USES THEREOF | ELI LILLY AND COMPANY (US) | 2024-12-05 | — | — | WO | disclosed |
| EP-4448765-A1 | MAPT RNA INTERFERENCE AGENTS | Eli Lilly and Company (US) | 2024-10-23 | — | — | EP | disclosed |
| US-11926827-B2 | MAPT RNA interference agents | ELI LILLY AND COMPANY (US) | 2024-03-12 | — | — | US | disclosed |
| US-20230340482-A1 | MAPT RNA INTERFERENCE AGENTS | ELI LILLY AND COMPANY | 2023-10-26 | — | — | US | disclosed |
| WO-2023177972-A1 | SARM1 RNA INTERFERENCE AGENTS | ELI LILLY AND COMPANY (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20230212576-A1 | MAPT RNA INTERFERENCE AGENTS | ELI LILLY AND COMPANY | 2023-07-06 | — | — | US | disclosed |
| WO-2023114700-A1 | MAPT RNA INTERFERENCE AGENTS | ELI LILLY AND COMPANY (US) | 2023-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188472-A1 | SARM1 RNA INTERFERENCE AGENTS | SARNP, SARM1, SMN1; SMN2 | ADORA1 4355/4885ADORA2A 4350/4885ADORA2B 4629/4885 |
| US-20260139257-A1 | PLIN1 RNAi INTERFERENCE AGENTS | PLIN1, PLIN3, PLIN5 | ADORA1 1878/4885ADORA2A 3741/4885ADORA2B 3761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.